Results 1 to 10 of about 340,431 (244)

Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. [PDF]

, 2020
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at risk of exacerbations and pneumonia; how the risk factors interact is unclear.
A Anzueto, B Majed, C Crim, C Crim, C Crim, CR Simpson, DB DiBardino, DB Rubin, DE Niewoehner, DT Phung, EF Wouters, FJ Martinez, Global Initiative for Chronic Obstructive Lung Disease, GS Collins, GT Ferguson, H Müllerova, H Müllerova, J Kim, J Vestbo, J Zhang, JA Wedzicha, JR Hurst, KM Kew, M Hamer, MB Drummond, MC Harpsøe, MI Restrepo, MT Dransfield, MT García Sanz, P Calverley, P Ernst, PM Calverley, RL DiSantostefano, RL DiSantostefano, S Siederer, S Singh, SD Neidich, SH Lin, SJ Pascoe, WM Chatila, Y Çolak, Y-F Wei, YS Jo   +42 more
core   +2 more sources

Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST) [PDF]

, 2020
BACKGROUND: Recurrent bronchiectasis exacerbations are related to deterioration of lung function, progression of the disease, impairment of quality of life, and to an increased mortality.
A Spinou, Adam T. Hill, AJ Mackay, AJ Mackay, AL Quittner, Anthony De Soyza, Arietta Spinou, CB Wilson, CS Haworth, David Araújo, EK Dudgeon, Eva Polverino, Eva Polverino, Irena F Laska, IS Patel, James D. Chalmers, MA Calderazzo, MP Murray, N Kapur, PW Jones, Roland Diel, Sanjay H. Chotirmall, SE Brill, SSC Kon, T McKeever, TA Seemungal, Timothy Aksamit   +26 more
core   +3 more sources

Indicators of pulmonary exacerbation in cystic fibrosis: A Delphi survey of patients and health professionals [PDF]

, 2015
Background: There is uncertainty about the most important indicators of pulmonary exacerbations in CF. Methods: Two parallel Delphi surveys in 13 CF centres (UK and Ireland). Delphi 1: 31 adults with CF, ≥ one exacerbation over 12 months.
Abbott, Ahern, Barry Plant, Beretta, Bilton, Bowles, Bradley, Brenda O'Neill, Britto, Cystic Fibrosis Registry of Ireland, Dakin, de Boer, Elkins, Ellaffi, Elpern, European Medicines Agency, Evie McCrum-Gardner, Ferkol, Fiona McCourt, Food and Drug Administration, Gee, Goss, Guyatt, Hasson, Ian Logan, J. Stuart Elborn, Janice Abbott, Jones, Judy M. Bradley, Juniper, Keeney, Keeney, Kraynack, Liou, Paranjape, Quittner, Stephanie McKeown, Survey Monkey, UK Cystic Fibrosis Registry   +38 more
core   +1 more source

The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. [PDF]

, 2016
Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD). Evidence suggests the presence of substantial between-individual variability (heterogeneity) in exacerbation rates.
Albert, Richard, Connett, John E, Criner, Gerard, Han, Meilan, Lazarus, Stephen, Martinez, Fernando, Sadatsafavi, Mohsen, Sin, Don D, Zafari, Zafar   +8 more
core   +1 more source

Beta(2)-adrenergic receptor (ADRB2) gene polymorphisms and risk of COPD exacerbations : the Rotterdam study [PDF]

, 2019
The role of the beta(2)-adrenergic receptor (ADRB2) gene in patients with chronic obstructive pulmonary disease (COPD) is unclear. We investigated the association between ADRB2 variants and the risk of exacerbations in COPD patients treated with inhaled ...
Brusselle, Guy, Ghanbari, Mohsen, Karimi, Leila, Lahousse, Lies, Stricker, Bruno H., Terzikhan, Natalie, Uitterlinden, Andre G., van der Lei, Johan, Verhamme, Katia   +8 more
core   +2 more sources

Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations [PDF]

, 2014
The FORWARD study is a randomised, double-blind trial that compares the efficacy and safety of 48 weeks treatment with extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI, 2 inhalations BID, vs. FOR 12 μg pMDI, 1 inhalation
Agusti, A, Bonnet-Gonod, F, Cohuet, G, Corradi, M, Jones, PW, Paggiaro, PL, Petruzzelli, S, Singh, D, Vestbo, J, Vezzoli, S, Wedzicha, JA   +10 more
core   +1 more source

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset [PDF]

, 2011
Acute periods of pulmonary exacerbation are the single most important cause of morbidity in cystic fibrosis patients, and may be associated with a loss of lung function.
Bruce, Kenneth D, Carroll, Mary P, Hoffman, Lucas R, Johnson, Matt W, Mayer-Hamblett, Nicole, Rogers, Geraint B, Schwarze, Jürgen   +6 more
core   +1 more source

Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]

, 2019
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke, Edris Mohamed, Ahmed, Joos, Guy, Lahousse, Lies, Maes, Tania   +4 more
core   +1 more source

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD [PDF]

, 2015
Objective We performed a review of studies of fluticasone propionate (FP)/salmeterol (SAL) (combination inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA)) in patients with COPD, which measured baseline (pretreatment) blood eosinophil levels, to ...
Barnes, NC, Jones, PW, Lettis, S, Locantore, N, Pascoe, S, Pavord, ID, Wedzicha, JA   +6 more
core   +1 more source

The effects of a physical activity counseling program after an exacerbation in patients with Chronic Obstructive Pulmonary Disease : a randomized controlled pilot study [PDF]

, 2015
Background: In some patients with COPD, the disease is characterized by exacerbations. Severe exacerbations warrant a hospitalization, with prolonged detrimental effects on physical activity.
Camillo, Carlos Augusto, Demeyer, Heleen, Hornikx, Miek, Janssens, Wim, Troosters, Thierry   +4 more
core   +2 more sources